These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

348 related items for PubMed ID: 9818655

  • 1. Autoantibodies against calpastatin in sera from patients with systemic sclerosis.
    Sato S, Hasegawa M, Nagaoka T, Takamatsu Y, Yazawa N, Ihn H, Kikuchi K, Takehara K.
    J Rheumatol; 1998 Nov; 25(11):2135-9. PubMed ID: 9818655
    [Abstract] [Full Text] [Related]

  • 2. Circulating anticentromere CENP-A and CENP-B antibodies in patients with diffuse and limited systemic sclerosis, systemic lupus erythematosus, and rheumatoid arthritis.
    Russo K, Hoch S, Dima C, Varga J, Teodorescu M.
    J Rheumatol; 2000 Jan; 27(1):142-8. PubMed ID: 10648030
    [Abstract] [Full Text] [Related]

  • 3. Anti-agalactosyl IgG antibodies in sera from patients with systemic sclerosis.
    Nishijima C, Sato S, Takehara K.
    J Rheumatol; 2001 Aug; 28(8):1847-51. PubMed ID: 11508588
    [Abstract] [Full Text] [Related]

  • 4. Anti-DNA topoisomerase II alpha autoantibodies in Japanese patients with systemic sclerosis.
    Hayakawa I, Hasegawa M, Takehara K, Sato S.
    Arch Dermatol Res; 2005 Oct; 297(4):180-3. PubMed ID: 16180014
    [Abstract] [Full Text] [Related]

  • 5. Rheumatoid factor isotypes and anti-agalactosyl IgG antibodies in systemic sclerosis.
    Mimura Y, Ihn H, Jinnin M, Asano Y, Yamane K, Yazawa N, Tamaki K.
    Br J Dermatol; 2004 Oct; 151(4):803-8. PubMed ID: 15491420
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Anti-DNA topoisomerase IIalpha autoantibodies in localized scleroderma.
    Hayakawa I, Hasegawa M, Takehara K, Sato S.
    Arthritis Rheum; 2004 Jan; 50(1):227-32. PubMed ID: 14730620
    [Abstract] [Full Text] [Related]

  • 10. Serum soluble CTLA-4 levels are increased in diffuse cutaneous systemic sclerosis.
    Sato S, Fujimoto M, Hasegawa M, Komura K, Yanaba K, Hayakawa I, Matsushita T, Takehara K.
    Rheumatology (Oxford); 2004 Oct; 43(10):1261-6. PubMed ID: 15266059
    [Abstract] [Full Text] [Related]

  • 11. Direct binding of anti-DNA topoisomerase I autoantibodies to the cell surface of fibroblasts in patients with systemic sclerosis.
    Hénault J, Tremblay M, Clément I, Raymond Y, Senécal JL.
    Arthritis Rheum; 2004 Oct; 50(10):3265-74. PubMed ID: 15476238
    [Abstract] [Full Text] [Related]

  • 12. Autoantibodies against matrix metalloproteinase-1 in patients with localized scleroderma.
    Tomimura S, Ogawa F, Iwata Y, Komura K, Hara T, Muroi E, Takenaka M, Shimizu K, Hasegawa M, Fujimoto M, Sato S.
    J Dermatol Sci; 2008 Oct; 52(1):47-54. PubMed ID: 18565735
    [Abstract] [Full Text] [Related]

  • 13. Decreased levels of autoantibody against histone deacetylase 3 in patients with systemic sclerosis.
    Kuwatsuka Y, Ogawa F, Iwata Y, Komura K, Muroi E, Hara T, Takenaka M, Shimizu K, Hasegawa M, Fujimoto M, Sato S.
    Autoimmunity; 2009 Feb; 42(2):120-5. PubMed ID: 19021012
    [Abstract] [Full Text] [Related]

  • 14. Autoantibody profiles in systemic sclerosis: predictive value for clinical evaluation and prognosis.
    Hamaguchi Y.
    J Dermatol; 2010 Jan; 37(1):42-53. PubMed ID: 20175839
    [Abstract] [Full Text] [Related]

  • 15. Serum concentrations of the CXC chemokines interleukin 8 and growth-regulated oncogene-alpha are elevated in patients with systemic sclerosis.
    Furuse S, Fujii H, Kaburagi Y, Fujimoto M, Hasegawa M, Takehara K, Sato S.
    J Rheumatol; 2003 Jul; 30(7):1524-8. PubMed ID: 12858452
    [Abstract] [Full Text] [Related]

  • 16. Serum levels of interleukin 6 (IL-6), oncostatin M, soluble IL-6 receptor, and soluble gp130 in patients with systemic sclerosis.
    Hasegawa M, Sato S, Fujimoto M, Ihn H, Kikuchi K, Takehara K.
    J Rheumatol; 1998 Feb; 25(2):308-13. PubMed ID: 9489824
    [Abstract] [Full Text] [Related]

  • 17. A novel autoantigen to differentiate limited cutaneous systemic sclerosis from diffuse cutaneous systemic sclerosis: the interferon-inducible gene IFI16.
    Mondini M, Vidali M, De Andrea M, Azzimonti B, Airò P, D'Ambrosio R, Riboldi P, Meroni PL, Albano E, Shoenfeld Y, Gariglio M, Landolfo S.
    Arthritis Rheum; 2006 Dec; 54(12):3939-44. PubMed ID: 17133607
    [Abstract] [Full Text] [Related]

  • 18. Elevated serum levels of interleukin 4 (IL-4), IL-10, and IL-13 in patients with systemic sclerosis.
    Hasegawa M, Fujimoto M, Kikuchi K, Takehara K.
    J Rheumatol; 1997 Feb; 24(2):328-32. PubMed ID: 9034992
    [Abstract] [Full Text] [Related]

  • 19. Serum levels of a Th1 chemoattractant IP-10 and Th2 chemoattractants, TARC and MDC, are elevated in patients with systemic sclerosis.
    Fujii H, Shimada Y, Hasegawa M, Takehara K, Sato S.
    J Dermatol Sci; 2004 Jun; 35(1):43-51. PubMed ID: 15194146
    [Abstract] [Full Text] [Related]

  • 20. High diagnostic value of anticalpastatin autoantibodies in rheumatoid arthritis detected by ELISA using human erythrocyte calpastatin as antigen.
    Iwaki-Egawa S, Matsuno H, Yudoh K, Nakazawa F, Miyazaki K, Ochiai A, Hirohata S, Shimizu M, Watanabe Y.
    J Rheumatol; 2004 Jan; 31(1):17-22. PubMed ID: 14705213
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.